Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Reports Successful Primary Endpoint in Phase 2 Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Successful MPSVI Safety Review and PARA OA 008 Update
- Successful Completion of Entitlement Offer
- 2022 Annual Report and Appendix 4E
- PAR Non-Renounceable Rights Issue Offer Booklet
- Investor Presentation - $66m Capital Raise
Later from Paradigm Biopharmaceuticals
- Paradigm Doses First UK Participant in Phase 3 Trial
- Paradigm Receives $7.4m R&D Tax Incentive Refund
- Paradigm CEO steps down & Appointment of MD
- PAR Receives Allowance for Key US Patent
- Phase 3 OA Trial to Proceed after Formal Safety Review
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals